La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Proto Labs a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Proto Labs..

Proto Labs (NYSE:PRLB) Azioni, Catena delle Opzioni

Proto Labs

Proto Labs Inc is an on-demand manufacturer of custom parts for prototyping and short-run production. The company offers developers and engineers quick-turn production services to reduce the time to market. Proto Labs uses injection molding, computer numerical control machining, and 3-D printing to manufacture custom parts for its clients. The company services clients' needs for prototype solutions, parts for testing procedures, bridge production capabilities during disruptions in manufacturing processes, limited-quantity requests, and end-of-life production support. The majority of its revenue is derived from the United States of America.

Proto Labs Inc

Shares of Charter Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) rose sharply in today's pre-market trading after the company reported better-than-expected <a href="https://www.benzinga.com/news/earnings/24/11/41684534/charter-communications-beats-q3-estimates-on-strong-mobile-growth-expanding-margins">third-quarter EPS and revenues.</a>
Charter Communications reported fiscal third-quarter 2024 revenue growth of 1.6% year-on-year to $13.8 billion, beating the analyst consensus estimate of $13.7 billion. EPS of $8.82 beat the analyst consensus estimate of $8.67
Charter Communications shares rose 11.1% to $364.01 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Globalstar, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSAT#NYSE">GSAT</a>) gained 41.9% to $1.49 in pre-market trading after the company announced a proposed public offering.</li>
<li>Theriva Biologics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#NYSE">TOVX</a>) rose 41.1% to $2.06 in pre-market trading after the company announced it was selected as a finalist for Merck KGaA&#8217;s EMEA Advance Biotech Grant.</li>
<li>Athira Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) shares surged 31.1% to $0.5610 in pre-market trading.</li>
<li>VS MEDIA Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSME#NASDAQ">VSME</a>) climbed 30% to $1.43 in pre-market trading after declining 11% on Thursday.</li>
<li>Atlassian Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) gained 22.5% to $231.06 in pre-market trading after the company reported better-than-expected first-quarter financial results and issued second-quarter revenue guidance above estimates.</li>
<li>Nuburu, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURU#NYSE">BURU</a>) gained 18.6% to $0.5340 in pre-market trading.</li>
<li>Proto Labs, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NYSE">PRLB</a>) gained 18.3% to $32.43 in pre-market trading after the company reported better-than-expected third-quarter financial results and issued fourth-quarter adjusted EPS guidance with its midpoint above estimates.</li>
<li>comScore, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCOR#NASDAQ">SCOR</a>) shares rose 17.3% to $6.45 in pre-market trading.</li>
<li>Halozyme Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) gained 12.8% to $57.04 in pre-market trading after the company reported better-than-expected third-quarter financial results and issued FY24 adjusted EPS guidance above estimates.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>ESSA Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPIX#NASDAQ">EPIX</a>) shares dipped 69.2% to $1.60 in pre-market trading. ESSA Pharma terminated Phase 2 study evaluating Masofaniten combined with Enzalutamide in patients with mCRPC.</li>
<li>Lexicon Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) fell 37.4% to $1.2207 in pre-market trading.</li>
<li>Elevai Labs Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>) fell 35% to $0.0383 in pre-market trading.</li>
<li>MultiMetaVerse Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMV#NASDAQ">MMV</a>) declined 24.1% to $0.3331 in pre-market trading.</li>
<li>Arbe Robotics Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBE#NASDAQ">ARBE</a>) declined 18.7% to $1.4800 in pre-market trading after the company announced a public offering.</li>
<li>Advent Technologies Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADN#NYSE">ADN</a>) fell 15.8% to $1.9899 in pre-market trading after jumping around 34% on Thursday.</li>
<li>ASP Isotopes Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASPI#NASDAQ">ASPI</a>) fell 8.4% to $6.40 in pre-market trading after the company announced a proposed public offering.</li>
<li>BJ&#8217;s Restaurants, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJRI#NASDAQ">BJRI</a>) fell 6.3% to $34.75 in today's pre-market trading after the company announced worse-than-expected third-quarter EPS results.</li>
<li>nVent Electric plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVT#NYSE">NVT</a>) shares fell 6.1% to $70.00 in pre-market trading after the company reported third-quarter results.</li>
<li>DigitalBridge Group, Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBRG#NASDAQ">DBRG</a>) declined 6% to $14.75 in pre-market trading after the company reported weaker-than-expected third-quarter results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41676524/s-p-500-records-worst-session-in-over-a-month-meta-and-microsoft-tumble-greed-index-moves-to-fear-z">S&amp;P 500 Records Worst Session In Over A Month, Meta And Microsoft Tumble: Greed Index Moves To &#8216;Fear&#8217; Zone</a></li>
</ul>

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ARBE

ASPI

ATHA

BJRI

BURU

CHTR

DBRG

ELAB

EPIX

GSAT

HALO

LXRX

Eaton Vance Massachusetts Municipal Income Trust

PRLB

SCOR

TEAM

TOVX

VSME

Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket

WIIM

Proto Labs shares are trading higher after the company reported better-than-expected Q3 financial results and issued Q4 adjusted EPS guidance with its midpoint above estimates.

Earnings

Guidance

General

Protolabs Expects Q4 Of 2024 Adjusted EPS Of $0.28-$0.36 Versus Consensus Of $0.29, With GAAP EPS Of $0.10-$0.18 Compared To Consensus Of $0.13

Protolabs Expects Q4 Of 2024 Revenue Of $115M-$123M Versus Consensus Of $120.01M

Proto Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NYSE">PRLB</a>) reported quarterly earnings of $0.47 per share which beat the analyst consensus estimate of $0.32 by 46.87 percent. This is a 7.84 percent decrease over earnings of $0.51 per share from the same period last year. The company reported quarterly sales of $125.62 million which beat the analyst consensus estimate of $121.38 million by 3.49 percent. This is a 3.89 percent decrease over sales of $130.71 million the same period last year.

Earnings Beats

Proto Labs Q3 2024 Adj EPS $0.47 Beats $0.32 Estimate, Sales $125.62M Beat $121.38M Estimate

Proto Labs, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/prlb#NYSE">PRLB</a>) announced that it launched Axtra3D Hybrid PhotoSynthesis technology, which expands its 3D printing capabilities. The launch of HPS complements Proto Labs&#39; strategy to meet additional customer needs and extend into production use cases.
<h2>PRLB&#39;s HPS to Complement Existing Capabilities</h2>
HPS employs a precision laser and a digital light processing system to capture images of internal and external part structures at the same time. This dual 3D printing approach helps overcome previous 3D printing limitations. Common HPS applications include production-grade components with high throughput parts. It requires high-accuracy features for testing and validation, and cosmetic prototypes with glass-like surface finishes.
HPS supports the company&#39;s existing Carbon digital light synthesis printers for 3D printing projects that demand better mechanical qualities.
<h2>Current Available HPS Materials Boost Proto Labs&#39; Potential</h2>
The two currently available HPS materials include Tough Black (Loctite Henkel 3843) and Ceramic-filled (BASF 3280).
Tough Black is an engineering-grade resin with great strength and exceptional impact resistance, whereas Ceramic-filled is a stiff substance commonly used for tooling and molding. Both materials increase the company&#39;s advanced photopolymer catalog and supplement the materials previously available for Carbon DLS.
<h2>PRLB Q2 Earnings Beat Estimates, Revenues Rise Y/Y</h2>
In the second quarter of 2024, Proto Labs reported a 3.3% year-over-year increase in revenues to $126 million. The top line met the Zacks Consensus Estimate. The company reported earnings per share of 18 cents against the loss of 1 cent posted in the second quarter of 2023. The bottom line beat the Zacks Consensus Estimate of 16 cents.
<h2>Proto Labs&#39; Share Price Performance</h2>
Proto Lab&#39;s shares have gained 0.4% in the past year against the industry&#39;s 16.6% decline.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/8c/77208.jpg?v=172366857" />
Image Source: Zacks Investment Research
<h2>PRLB&#39;s Zacks Rank &amp; Other Stocks to Consider</h2>
PRLB currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the Industrial Products sector are Crane Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cr#NYSE">CR</a>), Flowserve Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fls#NYSE">FLS</a>) and Cintas Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ctas#NASDAQ">CTAS</a>). These three companies have a Zacks Rank #2 at present.
The Zacks Consensus Estimate for Crane&#39;s 2024 earnings is pegged at $5.07 per share. The consensus estimate for 2024 earnings has moved north by 6% in the past 60 days. The company has a trailing four-quarter average earnings surprise of 11.2%. CR shares have gained 75.2% in a year.
Flowserve has an average trailing four-quarter earnings surprise of 18.2%. The Zacks Consensus Estimate for FLS&#39; 2024 earnings is pinned at $2.76 per share, which indicates year-over-year growth of 31.6%. The consensus estimate for 2024 earnings has moved north by 4% in the past 60 days. The company&#39;s shares have gained 27.5% in a year.
The Zacks Consensus Estimate for Cintas&#39; 2024 earnings is pegged at $16.64 per share. The consensus estimate for 2024 earnings has moved north by 1% in the past 60 days. The company has a trailing four-quarter average earnings surprise of 4%. CTAS shares have gained 60.4% in a year.
<a href="https://www.zacks.com/stock/news/2334207/proto-labs-launches-axtra3d-hps-technology-to-boost-capabilities?cid=CS-BENZ-FT-analyst_blog|company_news_corporate_actions-2334207">To read this article on Zacks.com click here.</a>

Large Cap

Mid Cap

Small Cap

Analyst Ratings

Tech

CTAS

Proto Labs Launches Axtra3D HPS Technology to Boost Capabilities

In a recent SEC filing, it was revealed that Robert Bodor, President and CEO at Proto Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NYSE">PRLB</a>), made a noteworthy insider purchase on September 9,.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001443669/000162828024039901//Archives/edgar/data/1443669/000162828024039901/0001628280-24-039901-index.htm">U.S. Securities and Exchange Commission</a> on Monday showed that Bodor purchased 3,480 shares of Proto Labs. The total transaction amounted to $99,800. 
As of Tuesday morning, Proto Labs shares are up by 0.93%, currently priced at $28.2.
<h3>About Proto Labs</h3>
Proto Labs Inc is an on-demand manufacturer of custom parts for prototyping and short-run production. The company offers developers and engineers quick-turn production services to reduce the time to market. Proto Labs uses injection molding, computer numerical control machining, and 3-D printing to manufacture custom parts for its clients. The company services clients' needs for prototype solutions, parts for testing procedures, bridge production capabilities during disruptions in manufacturing processes, limited-quantity requests, and end-of-life production support. The majority of its revenue is derived from the United States of America.
<h3>Proto Labs: A Financial Overview</h3>
Revenue Growth: Proto Labs's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 2.75%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.
Exploring Profitability:
<ul>
<li>
Gross Margin: With a high gross margin of 45.01%, the company demonstrates effective cost control and strong profitability relative to its peers.
</li>
<li>
Earnings per Share (EPS): Proto Labs's EPS is below the industry average. The company faced challenges with a current EPS of 0.18. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: Proto Labs's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
Analyzing Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 29.41 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a lower-than-average P/S ratio of 1.41, the stock presents an attractive valuation, potentially signaling a buying opportunity for investors interested in sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio of 8.69 trails industry averages, indicating a potential disparity in market valuation that could be advantageous for investors.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Relevance of Insider Transactions</h3>
It's important to note that insider transactions alone should not dictate investment decisions, but they can provide valuable insights.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>Unlocking the Meaning of Transaction Codes</h3>
When dissecting transactions, the focal point for <a href="https://www.benzinga.com/money/investing-tools">investors</a> is often those occurring in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001443669">Check Out The Full List Of Proto Labs's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Proto Labs President and CEO Makes $99K Stock Purchase

Axtra3D printing capabilities complement digital manufacturer's advanced photopolymer offering with highly precise and repeatable printed parts in days.
Digital manufacturing leader Protolabs expanded its 3D printing capabilities today with the launch of an <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.protolabs.com%2Fservices%2F3d-printing%2Fadvanced-photopolymers%2F&amp;esheet=54118617&amp;newsitemid=20240909892648&amp;lan=en-US&amp;anchor=advanced+photopolymers+technology&amp;index=1&amp;md5=6d53469f2c8adbd656e5c371c04611e0">advanced photopolymers technology</a>. Axtra3D Hybrid PhotoSynthesis (HPS) offers highly repeatable and finely detailed 3D printed parts at accelerated speeds. HPS uses both a precision laser and digital light processing (DLP) system to simultaneously image internal and external part structures—a dual 3D printing approach that overcomes traditional limitations.
HPS complements Protolabs' current Carbon digital light synthesis (DLS) printers for 3D printing projects that require stronger mechanical properties. Both Carbon DLS and HPS feature near-isotropic parts and smooth surface finishes, but HPS technology also offers exceptionally high resolution when compared to other 3D printing processes.

Protolabs Expands 3D Printing Options with Hybrid PhotoSynthesis Technology; Axtra3D Hybrid Photosynthesis Offers Highly Repeatable And Finely Detailed 3D Printed Parts At Accelerated Speeds

Needham analyst James Ricchiuti reiterates Proto Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NYSE">PRLB</a>) with a Hold.

Reiteration

Needham Reiterates Hold on Proto Labs

Proto Labs shares are trading lower after the company reported mixed Q2 financial results and issued Q3 guidance below estimates.

Third Quarter&nbsp;2024&nbsp;Outlook
For the&nbsp;third quarter&nbsp;of 2024, the Company expects to generate revenue between&nbsp;$117 million&nbsp;and&nbsp;$125 million.
The Company expects&nbsp;third quarter&nbsp;2024 diluted net income per share between&nbsp;$0.10&nbsp;and&nbsp;$0.18, and non-GAAP diluted net income per share between&nbsp;$0.29&nbsp;and&nbsp;$0.37. See &quot;Non-GAAP Financial Measures&quot; below.

Protolabs Expects Q3 Revenue Of $117M-$125M Vs. $129.624M Consensus; Sees Adj. EPS Of $0.29-$0.37 Vs. $0.41 Consensus

Proto Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NYSE">PRLB</a>) reported quarterly earnings of $0.38 per share which beat the analyst consensus estimate of $0.35 by 8.57 percent. This is a 15.15 percent increase over earnings of $0.33 per share from the same period last year. The company reported quarterly sales of $125.631 million which missed the analyst consensus estimate of $126.245 million by 0.49 percent. This is a 2.75 percent increase over sales of $122.265 million the same period last year.

Earnings Misses

Proto Labs Q2 2024 Adj. EPS $0.38 Beats $0.35 Estimate, Sales $125.631M Miss $126.245M Estimate

During the last three months, 4 analysts shared their evaluations of Proto Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NYSE">PRLB</a>), revealing diverse outlooks from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $41.75, a high estimate of $45.00, and a low estimate of $34.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 1.37%. 
<img src="https://www.benzinga.com/files/images/story/2024/1722366021_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Proto Labs is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Troy Jensen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$44.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Troy Jensen</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$44.00</td>
<td>-</td>
</tr>
<tr>
<td>Robert Wasserman</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Greg Palm</td>
<td>Craig-Hallum</td>
<td>Lowers</td>
<td>Hold</td>
<td>$34.00</td>
<td>$38.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Proto Labs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Proto Labs compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Proto Labs's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Proto Labs's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PRLB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Proto Labs analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Proto Labs</h2>
Proto Labs Inc is an on-demand manufacturer of custom parts for prototyping and short-run production. The company offers developers and engineers quick-turn production services to reduce the time to market. Proto Labs uses injection molding, computer numerical control machining, and 3-D printing to manufacture custom parts for its clients. The company services clients' needs for prototype solutions, parts for testing procedures, bridge production capabilities during disruptions in manufacturing processes, limited-quantity requests, and end-of-life production support. The majority of its revenue is derived from the United States of America.
<h3>Proto Labs: A Financial Overview</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Proto Labs's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 1.61% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: Proto Labs's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.12% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 0.76%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Proto Labs's ROA excels beyond industry benchmarks, reaching 0.68%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Critical Insights From Proto Labs Analyst Ratings: What You Need To Know

Cantor Fitzgerald analyst Troy Jensen reiterates Proto Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NYSE">PRLB</a>) with a Overweight and maintains $44 price target.

Price Target

Cantor Fitzgerald Reiterates Overweight on Proto Labs, Maintains $44 Price Target

Cantor Fitzgerald analyst Troy Jensen initiated coverage on Proto Labs, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NYSE">PRLB</a>) with an Overweight rating <a target="_blank" href="https://www.benzinga.com/quote/PRLB/analyst-ratings" rel="noreferrer noopener">and price target of $44.00</a>.
The analyst writes that the company is well-placed to capitalize on a growing market and capture increased growth in production applications. With its hybrid business model offering in-house manufacturing and a network of suppliers, Proto Labs stands out in the digital manufacturing market, says the analyst.
Proto Labs is primed to benefit from the ongoing shift towards digital manufacturing, and its entirely digital end-to-end manufacturing service resonates with customers, offering a wide range of capabilities, says the analyst.
The analyst expects pent-up industry demand led by improving economic conditions and factors like declining interest rates and a more favorable economic environment are expected to drive growth reacceleration in the digital manufacturing sector.
The analyst notes that Proto Labs&#8217; near-term focus on growing revenues and expanding margins should benefit PRLB shares.
The analyst&#8217;s industry survey indicates a promising outlook for 2024, with around 91% of service bureaus expecting year-over-year revenue growth.
The analyst estimates EPS of $1.50 in FY24 and $1.71 in FY25.
Investors can gain exposure to the stock via&nbsp;3D Printing (The) ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/PRNT#BATS">PRNT</a>) and Pacer BlueStar Engineering The Future ETF&nbsp; (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BULD#NASDAQ">BULD</a>).
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/05/38614470/proto-labs-scores-first-quarter-beat-fueled-by-order-growth-higher-margin-factory-business" rel="noreferrer noopener">Proto Labs Scores First-Quarter Beat, Fueled By Order Growth, Higher-Margin Factory Business</a>
Price Action: PRLB shares are up 4.95% at $31.82 at the last check Wednesday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Analyst Color

Equities

Initiation

BULD

PRNT

Proto Labs Positioned For Growth: Analyst Predicts Strong Gains Amid Digital Manufacturing Surge

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>Guggenheim analyst Subbu Nambi initiated coverage on Twist Bioscience Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) with a Buy rating, while announcing a price target of $53. Twist Bioscience shares gained 6.8% to close at $46.98 on Tuesday. <a href="https://www.benzinga.com/quote/TWST/analyst-ratings">See how other analysts view this stock.</a></li>
<li>BMO Capital analyst Fadi Chamoun initiated coverage on Old Dominion Freight Line, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>) with an Outperform rating and announced a price target of $210. Old Dominion Freight Line shares rose 1.7% to settle at $172.14 on Tuesday. <a href="https://www.benzinga.com/quote/ODFL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cantor Fitzgerald analyst Troy Jensen initiated coverage on Proto Labs, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NYSE">PRLB</a>) with an Overweight rating, while announcing a price target of $44. Proto Labs shares fell 0.2% to settle at $30.32 on Tuesday. <a href="https://www.benzinga.com/quote/PRLB/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs analyst Madhu Kumar initiated coverage on Jazz Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Buy rating and announced a price target of $169. Jazz Pharmaceuticals shares fell 1.2% to close at $104.48 on Tuesday. <a href="https://www.benzinga.com/quote/JAZZ/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Craig-Hallum analyst Jeff Van Rhee initiated coverage on Spire Global, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NYSE">SPIR</a>) with a Buy rating, while announcing a price target of $13. Spire Global shares rose 1.1% to settle at $9.33 on Tuesday. <a href="https://www.benzinga.com/quote/SPIR/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/06/39181356/top-4-health-care-stocks-that-are-preparing-to-pump-this-month">Top 4 Health Care Stocks That Are Preparing To Pump This Month</a>

JAZZ

ODFL

SPIR

TWST

This Old Dominion Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Cantor Fitzgerald analyst Troy Jensen initiates coverage on Proto Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NYSE">PRLB</a>) with a Overweight rating and announces Price Target of $44.

Cantor Fitzgerald Initiates Coverage On Proto Labs with Overweight Rating, Announces Price Target of $44

Benchmark analyst Robert Wasserman reiterates Proto Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NYSE">PRLB</a>) with a Buy and maintains $45 price target.

Benchmark Reiterates Buy on Proto Labs, Maintains $45 Price Target

Craig-Hallum analyst Greg Palm maintains Proto Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NYSE">PRLB</a>) with a Hold and lowers the price target from $38 to $34.

Craig-Hallum Maintains Hold on Proto Labs, Lowers Price Target to $34

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
3D printing doesn&rsquo;t exactly conjure up the image of manufacturing. Yet, that&rsquo;s exactly what it is &mdash; only this time, it involves special computer-controlled lasers that build up items from scratch.&nbsp;



The more descriptive moniker for this technology is additive manufacturing, seeing as it&rsquo;s the opposite of traditional, subtractive manufacturing that involves cutting away material to achieve a final product.



More companies are now going for 3D printing because it allows them to create more intricate designs that are hard or impossible to achieve with traditional manufacturing.



The 3D printing industry is projected to expand dramatically over the next few years. Projections indicate it could reach almost $45 billion worldwide by 2027, according to a <a href="https://www.hubs.com/get/trends/">report by Hubs.</a>



Here are 3D printing stocks with some of the most promising industrial applications.&nbsp;



<h2>Autodesk (ADSK)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/11/autodesk_adsk1600-300x169.jpg" alt="An Autodesk (ADSK) sign on an office in Toronto, Canada."><div>Source: JHVEPhoto / Shutterstock.com</div></div>Autodesk (NASDAQ:<a href="https://investorplace.com/stock-quotes/adsk-stock-quote/">ADSK</a>) is a computer-aided design (CAD) software maker. The San Francisco, California-based company&rsquo;s solutions are used by companies in the construction, engineering and manufacturing fields, but also those in media and automotive. It has a flagship product, AutoCAD, which businesses can use to create detailed 2D and 3D designs cheaper and faster.&nbsp;



Autodesk has worked with some of the biggest names on the planet. Iconic landmarks and companies like the World Trade Center and Tesla (NASDAQ:<a href="https://investorplace.com/stock-quotes/tsla-stock-quote/">TSLA</a>) are just some of them.&nbsp;



The firm has what it calls Autodesk Fusion &mdash; a 3D printing software that supports businesses in the healthcare, aerospace and architecture industries.



In healthcare, for example, it can design accurate, custom prosthetics for patients.&nbsp;And, in aerospace, Fusion can help create lightweight components for airplanes to address the increasing need for better fuel efficiency and lower emissions.&nbsp;



Another promising application of Autodesk&rsquo;s 3D printing is prototyping. Manufacturing companies use prototyping, creating physical samples of a new product to test and improve them to ensure the final product meets quality standards.



These use cases make Autodesk one of the most promising 3D printing stocks in the market.



<h2>Protolabs (PRLB)</h2>



<div><img width="300" height="165" src="https://investorplace.com/wp-content/uploads/2018/08/3dprintingmsn2-300x165.jpg" alt=""><div>Source: Shutterstock</div></div>Protolabs (NYSE:<a href="https://investorplace.com/stock-quotes/prlb-stock-quote/">PRLB</a>) started out by designing a software that sped up the production of injection-molded plastic prototypes. It later added <a href="https://astromachineworks.com/what-is-cnc-machining/#:~:text=Computer%20Numerical%20Control%20(CNC)%20machining,to%20mills%20and%20CNC%20routers.">CNC machining</a> before rolling out a 3D printing service in 2014. Its business, which comprises hundreds of manufacturers under one umbrella, <a href="https://www.protolabs.com/services/3d-printing/">currently has</a> over 120 3D printers and a client roster of over 50,000 customers under its belt, making it a strong pick for 3D printing stocks.



Though it serves several industries, it has honed down on aerospace, medical, consumer electronics and robotics and automation.



Aviation companies can get 3D-printed aerodynamic parts. Medical companies working on medical imaging devices and stem cell research can also order custom-made parts from the company.



Also, robotics companies get to work with highly effective robots and automated equipment. And electronics manufacturers can put together stylish features for audio, video and gaming.



<h2>HP (HPQ)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/hpq-stock-2-300x169.jpg" alt=""><div>Source: Ken Wolter / Shutterstock.com</div></div>HP (NYSE:<a href="https://investorplace.com/stock-quotes/hpq-stock-quote/">HPQ</a>) has a stack of several 3D printers, including the HP Jet Fusion 5600 Series Industrial 3D Printing Solution and the S100 3D Printing Solution. The business helps companies in robotics, manufacturing, agriculture and housing design quality, 3D-printed parts to improve productivity and reduce costs.&nbsp;



Robotics companies can rethink how they design and build custom robotics and grippers. The result is strong parts that are lightweight and tailor-made to fit into the latest robotic systems.



Agriculture is another area where HP&rsquo;s 3D printing is changing the game. For instance, John Deere (NYSE:<a href="https://investorplace.com/stock-quotes/de-stock-quote/">DE</a>) factories across the globe are deploying HP&rsquo;s Metal Jet technology to produce thousands of tools, jigs and fixtures faster than before.&nbsp;



Those are just some of the industrial applications for HP&rsquo;s 3D printing tech. As the industry continues to mature, it&rsquo;ll continue to be one of the most exciting 3D printing stocks to watch.&nbsp;



On the date of publication, Hope Mutie did not have (either directly or indirectly) any positions in the stocks mentioned in this article. The opinions expressed in this article are those of the writer, subject to InvestorPlace.com&rsquo;s <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/#:~:text=InvestorPlace.com%20asks%20writers%20to,strive%20to%20link%20to%20it.">Publishing Guidelines.</a>



On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
<div>Hope Mutie is a writer who&rsquo;s enthusiastic about finance and crypto. At InvestorPlace, she keeps her finger on the pulse of the stock and crypto markets to create insightful and info-rich content to help investors navigate the market with confidence.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>
The post <a href="https://investorplace.com/2024/08/3-3d-printing-stocks-with-promising-industrial-applications/">3 3D Printing Stocks With Promising Industrial Applications</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

3 3D Printing Stocks With Promising Industrial Applications

Proto Labs ( ($PRLB) ) has issued an announcement. Bjoern Klaas, the ex-Vice President and General Manager of Proto Labs' EMEA region, has reached ...

Proto Labs Finalizes Exit Agreement with Ex-VP Klaas

Proto Labs to shut down facilities in Germany; incur up to $6M restructuring charges

In a report released today, Greg Palm from Craig-Hallum assigned a Hold rating to Proto Labs (PRLB – Research Report). The company's shares closed ...

Proto Labs (PRLB) Receives a Hold from Craig-Hallum

Companies in the Industrial Goods sector have received a lot of coverage today as analysts weigh in on Proto Labs (PRLB – Research Report) and Orio...

Analysts Offer Insights on Industrial Goods Companies: Proto Labs (PRLB) and Orion Group Holdings (ORN)

Proto Labs Q3 2024 Earnings Preview

Here's the major earnings before the open tomorrow

Proto Labs Non-GAAP EPS of $0.47 beats by $0.15, revenue of $125.6M beats by $4.22M

Sees Q4 revenue $115M-$123M, consensus $120.01M. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial ne...

Protolabs sees Q4 non-GAAP EPS 28c-36c, consensus 29c

Reports Q3 revenue $125.6M, consensus $121.38M. "Our disciplined approach and resilient business model drove solid financial results in Q3, despite...

Protolabs reports Q3 non-GAAP EPS 47c, consensus 32c

ACDVF

ADSK

ARCB

ARES

ASIX

BFLY

CBOE

CMLS

ESNT

FUBO

GTLS

INTT

MSGS

OXLC

TROW

Press Releases

PRLB Investors Have Opportunity to Join Proto Labs, Inc. Fraud Investigation with the Schall Law Firm

Legal

Proto Labs, Inc. (PRLB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Comments

Proto Labs

Proto Labs (PRLB) Opzioni

Proto Labs (NYSE:PRLB) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO